BeiGene therapies get expanded coverage on China's national reimbursement drug list
ljubaphoto/E+ via Getty Images


BeiGene (NASDAQ:BGNE) and Novartis' (NVS) tislelizumab's four new indications were added to the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA).
Tislelizumab's new indications include to treat a type of non-small cell lung cancer (NSCLC); patients with solid tumors including a type of colorectal cancer; esophageal squamous cell carcinoma; and nasopharyngeal cancer.

The company noted that tislelizumab's all nine approved indications now included in NRDL.
The NRDL also included multiple myeloma therapy Kyprolis (carfilzomib), and Xgeva (denosumab) to treat giant cell tumor of the bone, both developed by Amgen (AMGN).
"The expanded coverage of tislelizumab, new inclusion of KYPROLIS, as well as the renewal of XGEVA on the latest NRDL will allow more patients in China to have access to these high-quality medicines at affordable prices," said Xiaobin Wu, president, COO and general manager of China, at BeiGene.